FDA OPDP Boxed Warning Marketing Standards
Promotion of drugs with a boxed warning must convey the boxed-warning risk with prominence comparable to benefit claims, and reminder ads are not permitted for these drugs.
Promotion of drugs with a boxed warning must convey the boxed-warning risk with prominence comparable to benefit claims, and reminder ads are not permitted for these drugs.
Prescription drug ads that name a drug and its use must present risk information with prominence comparable to benefit claims and must not overstate efficacy or safety.
Disease-awareness ads from drug firms may discuss a condition and urge a doctor visit but must not name, cue or point to a specific drug; if they do, they become product ads needing risk information.
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.
Prescription drug promotion must not depict or target age groups outside the approved indication and must include labeled age-specific risks when targeting that group.
Reminder ads may name a prescription drug with limited facts but may not state or imply its use or make claims, and are not allowed for drugs with boxed warnings.
Social and character-limited posts that name a prescription drug and its benefit must state the most serious risks in the post and link to complete risk information.